MedTrace Logo

GnRH for Luteal Support - Mechanism of Action

NCT07620067 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-06-02

No results posted yet for this study

Summary

This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger according to OHSS risk. After oocyte retrieval and fertilization by IVF/ICSI, embryos will be cultured and transferred. Luteal phase support will consist of either intranasal GnRH agonist (Synarel) or vaginal progesterone. Blood and follicular fluid samples will be collected at predefined time points to assess hormonal, inflammatory, and angiogenic markers, including LH, FSH, estradiol, progesterone, IL-6, IL-8, VEGF, PEDF, and relaxin.

Conditions

  • GnRH Antagonist IVF Protocol
  • Fresh Embryo Transfer
  • Administration of Hormonal Luteal Support

Interventions

DRUG

GnRH agonist

spray of 200 mcg Nafarelin (Synarel) twice a day for two weeks

DRUG

Progesterone

PV progesterone administered until hCG day and continued for 8-10

Sponsors & Collaborators

  • Heli Alexandroni

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07620067 on ClinicalTrials.gov